Id |
Subject |
Object |
Predicate |
Lexical cue |
TextSentencer_T1 |
0-124 |
Sentence |
denotes |
Glycosylation profiles of epitope-specific anti-beta-amyloid antibodies revealed by liquid chromatography-mass spectrometry. |
T1 |
0-124 |
Sentence |
denotes |
Glycosylation profiles of epitope-specific anti-beta-amyloid antibodies revealed by liquid chromatography-mass spectrometry. |
T1 |
0-124 |
Sentence |
denotes |
Glycosylation profiles of epitope-specific anti-beta-amyloid antibodies revealed by liquid chromatography-mass spectrometry. |
TextSentencer_T2 |
125-206 |
Sentence |
denotes |
Alzheimer's disease (AD) is the most prevalent form of age-related neurodementia. |
T2 |
125-206 |
Sentence |
denotes |
Alzheimer's disease (AD) is the most prevalent form of age-related neurodementia. |
T2 |
125-206 |
Sentence |
denotes |
Alzheimer's disease (AD) is the most prevalent form of age-related neurodementia. |
TextSentencer_T3 |
207-315 |
Sentence |
denotes |
The accumulation of beta-amyloid polypeptide (Abeta) in brain is generally believed to be a key event in AD. |
T3 |
207-315 |
Sentence |
denotes |
The accumulation of beta-amyloid polypeptide (Abeta) in brain is generally believed to be a key event in AD. |
T3 |
207-315 |
Sentence |
denotes |
The accumulation of beta-amyloid polypeptide (Abeta) in brain is generally believed to be a key event in AD. |
TextSentencer_T4 |
316-457 |
Sentence |
denotes |
The recent discovery of physiological beta-amyloid autoantibodies represents a promising perspective for treatment and early diagnosis of AD. |
T4 |
316-457 |
Sentence |
denotes |
The recent discovery of physiological beta-amyloid autoantibodies represents a promising perspective for treatment and early diagnosis of AD. |
T4 |
316-457 |
Sentence |
denotes |
The recent discovery of physiological beta-amyloid autoantibodies represents a promising perspective for treatment and early diagnosis of AD. |
TextSentencer_T5 |
458-566 |
Sentence |
denotes |
The mechanisms by which natural beta-amyloid autoantibodies prevent neurodegeneration are currently unknown. |
T5 |
458-566 |
Sentence |
denotes |
The mechanisms by which natural beta-amyloid autoantibodies prevent neurodegeneration are currently unknown. |
T5 |
458-566 |
Sentence |
denotes |
The mechanisms by which natural beta-amyloid autoantibodies prevent neurodegeneration are currently unknown. |
TextSentencer_T6 |
567-825 |
Sentence |
denotes |
The aim of the present study was to analyze the N-linked glycosylation of a plaque-specific, monoclonal antibody (clone 6E10) relevant for immunotherapy of AD, in comparison with the glycosylation pattern of an Abeta autoantibody isolated from an IgG source. |
T6 |
567-825 |
Sentence |
denotes |
The aim of the present study was to analyze the N-linked glycosylation of a plaque-specific, monoclonal antibody (clone 6E10) relevant for immunotherapy of AD, in comparison with the glycosylation pattern of an Abeta autoantibody isolated from an IgG source. |
T6 |
567-825 |
Sentence |
denotes |
The aim of the present study was to analyze the N-linked glycosylation of a plaque-specific, monoclonal antibody (clone 6E10) relevant for immunotherapy of AD, in comparison with the glycosylation pattern of an Abeta autoantibody isolated from an IgG source. |
TextSentencer_T7 |
826-1019 |
Sentence |
denotes |
Liquid chromatography in combination with tandem mass spectrometry was used to analyze the glycopeptides generated by enzymatic degradation of the antibodies reduced and alkylated heavy chains. |
T7 |
826-1019 |
Sentence |
denotes |
Liquid chromatography in combination with tandem mass spectrometry was used to analyze the glycopeptides generated by enzymatic degradation of the antibodies reduced and alkylated heavy chains. |
T7 |
826-1019 |
Sentence |
denotes |
Liquid chromatography in combination with tandem mass spectrometry was used to analyze the glycopeptides generated by enzymatic degradation of the antibodies reduced and alkylated heavy chains. |
TextSentencer_T8 |
1020-1230 |
Sentence |
denotes |
The oligosaccharide pattern of the 6E10 antibody shows primarily core-fucosylated biantennary complex structures and, to a low extent, tri- and tetragalactosyl glycoforms, with or without terminal sialic acids. |
T8 |
1020-1230 |
Sentence |
denotes |
The oligosaccharide pattern of the 6E10 antibody shows primarily core-fucosylated biantennary complex structures and, to a low extent, tri- and tetragalactosyl glycoforms, with or without terminal sialic acids. |
T8 |
1020-1230 |
Sentence |
denotes |
The oligosaccharide pattern of the 6E10 antibody shows primarily core-fucosylated biantennary complex structures and, to a low extent, tri- and tetragalactosyl glycoforms, with or without terminal sialic acids. |
TextSentencer_T9 |
1231-1551 |
Sentence |
denotes |
The glycans associated with the serum anti-Abeta autoantibodies are of the complex, biantennary-type, fucosylated at the first N-acetyl glucosamine residue of the trimannosyl chitobiose core and contain zero to two galactose residues, and zero to one terminal sialic acid, with or without bisecting N-acetyl glucosamine. |
T9 |
1231-1551 |
Sentence |
denotes |
The glycans associated with the serum anti-Abeta autoantibodies are of the complex, biantennary-type, fucosylated at the first N-acetyl glucosamine residue of the trimannosyl chitobiose core and contain zero to two galactose residues, and zero to one terminal sialic acid, with or without bisecting N-acetyl glucosamine. |
T9 |
1231-1551 |
Sentence |
denotes |
The glycans associated with the serum anti-Abeta autoantibodies are of the complex, biantennary-type, fucosylated at the first N-acetyl glucosamine residue of the trimannosyl chitobiose core and contain zero to two galactose residues, and zero to one terminal sialic acid, with or without bisecting N-acetyl glucosamine. |
TextSentencer_T10 |
1552-1722 |
Sentence |
denotes |
Glycosylation analysis of the Abeta-autoantibody performed at the peptide level revealed all four human IgG subclasses, with IgG(1) and IgG(2) as the dominant subclasses. |
T10 |
1552-1722 |
Sentence |
denotes |
Glycosylation analysis of the Abeta-autoantibody performed at the peptide level revealed all four human IgG subclasses, with IgG(1) and IgG(2) as the dominant subclasses. |
T10 |
1552-1722 |
Sentence |
denotes |
Glycosylation analysis of the Abeta-autoantibody performed at the peptide level revealed all four human IgG subclasses, with IgG(1) and IgG(2) as the dominant subclasses. |